Evaluation of the applicability of BI-RADS® MRI for the interpretation of contrast-enhanced digital mammography

Travieso-Aja, M. M.; Maldonado-Saluzzi, D.; Naranjo-Santana, P.; Fernandez-Ruiz, C; Severino-Rondón, W.; Rodríguez, Mario; Luzardo, Octavio P.

doi:10.1016/j.rxeng.2019.07.003

Cited by 6 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Heterogeneous of enhancement was the most common enhancement pattern encountered in our series seen in 49.2% of cases. Our findings were consistent with previous investigators who reported that masses eliciting heterogeneous enhancement showed a significantly higher tendency of malignancy compared to masses with homogeneous enhancement [26,37,38]. NME was the second most common pattern observed in our series in line with the Kamal et al [26] and Wilhelm et al [39], who reported strong correlation between NME and malignant pathology with P values of ≤ 0.001.…”

Section: Discussionsupporting

confidence: 93%

Mammographic and contrast-enhanced spectral mammography imaging findings of HER2-positive cancers according to hormone receptor status

Elkassas

Helal

Mikhael

et al. 2022

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background Breast cancer is the leading cause of cancer-related mortality in women. Human epidermal growth factor receptor 2 (HER2) overexpression is seen in 20 out of 100 invasive breast cancers. Among HER2+ patients, two distinct hormone receptor (HR) subtypes can be defined: HR-positive (HR+) and HR-negative (HR−) each of which with unique therapeutic response and survival pattern. Contrast-enhanced spectral mammography (CESM) is an emerging novel imaging modality that offers diagnostic performance comparable to contrast-enhanced MRI. The purpose of this retrospective study was to describe the CESM features of HER2+ breast cancers according to hormone receptor status and to assess whether specific mammographic and CESM imaging features can differentiate between HER2+/HR+ and HER2+/HR− breast cancers potentially aiding treatment planning in HER2+ breast cancer patients. Results A total of 61 patients were included. Twenty-nine cases (47.5%) were HER2+/HR+ and 32 cases (52.5%) were HER2+/HR−. No statistically significant difference was found between mammographic imaging presentations and hormonal status. HR- were more likely to be multifocal (P 0.018), rounded or oval (P 0.008), circumscribed (P 0.004), and with associated non-mass enhancement (NME) (P < 0.001). HR+ cancers showed a tendency for irregular shape (P 0.008), spiculated outline (P 0.004), and heterogeneous (P 0.021) or ring (P 0.046) enhancement. Conclusions HER2+ tumors have different demographic, pathologic and imaging features according to the hormone receptor status. Because the two subtypes of HER2 breast cancer have different clinical outcomes, CESM imaging features can potentially enhance patient outcome by accelerating the diagnosis and treatment.

show abstract

Section: Discussionsupporting

confidence: 93%

Mammographic and contrast-enhanced spectral mammography imaging findings of HER2-positive cancers according to hormone receptor status

Elkassas

Helal

Mikhael

et al. 2022

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

show abstract

“…Most specified that 1.5ml/kg intravenous iodinated contrast agent was administered at 3ml/sec. (10)(11)(12)(13)(14) There was variation in the image acquisition protocols between papers, however this is felt to reflect normal clinical practice and should not invalidate results.…”

Section: Intensity and Pattern Of Lesion Enhancementmentioning

confidence: 99%

Quantifying lesion enhancement on contrast-enhanced mammography: a review of published data

Savaridas

Tennant

2022

Clinical Radiology

View full text Add to dashboard Cite

“…A lexicon serves as a collection of consistent terms used to concisely and accurately describe imaging findings. Various studies have certified lexicons for different imaging modalities [16,17]. The 5th edition of BI-RADS harmonizes terminology across mammography, ultrasound (US), and breast MRI, enabling precise correspondence between these modalities, facilitating communication among radiologists, and ensuring consistent reporting to referring clinicians [8].…”

Section: Bi-rads Lexiconmentioning

confidence: 99%

“…Studies have attempted to adapt existing descriptors for these recent modalities. For instance, various studies assessing the applicability of MRI BI-RADS descriptors to CEM have indicated that mass lesion features yield the most consistent results across MRI and CEM [16,17]. Similarly, the BI-RADS lexicon has been customized for MBI and PEM, incorporating recommendations for lesion features and relevant molecular agent uptake [19,20].…”

Section: Bi-rads Lexiconmentioning

confidence: 99%

Impact of Imaging Biomarkers and AI on Breast Cancer Management: A Brief Review

Saleh,

Batouty,

Gamal

et al. 2023

Cancers

View full text Add to dashboard Cite

Breast cancer stands out as the most frequently identified malignancy, ranking as the fifth leading cause of global cancer-related deaths. The American College of Radiology (ACR) introduced the Breast Imaging Reporting and Data System (BI-RADS) as a standard terminology facilitating communication between radiologists and clinicians; however, an update is now imperative to encompass the latest imaging modalities developed subsequent to the 5th edition of BI-RADS. Within this review article, we provide a concise history of BI-RADS, delve into advanced mammography techniques, ultrasonography (US), magnetic resonance imaging (MRI), PET/CT images, and microwave breast imaging, and subsequently furnish comprehensive, updated insights into Molecular Breast Imaging (MBI), diagnostic imaging biomarkers, and the assessment of treatment responses. This endeavor aims to enhance radiologists’ proficiency in catering to the personalized needs of breast cancer patients. Lastly, we explore the augmented benefits of artificial intelligence (AI), machine learning (ML), and deep learning (DL) applications in segmenting, detecting, and diagnosing breast cancer, as well as the early prediction of the response of tumors to neoadjuvant chemotherapy (NAC). By assimilating state-of-the-art computer algorithms capable of deciphering intricate imaging data and aiding radiologists in rendering precise and effective diagnoses, AI has profoundly revolutionized the landscape of breast cancer radiology. Its vast potential holds the promise of bolstering radiologists’ capabilities and ameliorating patient outcomes in the realm of breast cancer management.

show abstract

Evaluation of the applicability of BI-RADS® MRI for the interpretation of contrast-enhanced digital mammography

Cited by 6 publications

References 37 publications

Mammographic and contrast-enhanced spectral mammography imaging findings of HER2-positive cancers according to hormone receptor status

Mammographic and contrast-enhanced spectral mammography imaging findings of HER2-positive cancers according to hormone receptor status

Quantifying lesion enhancement on contrast-enhanced mammography: a review of published data

Impact of Imaging Biomarkers and AI on Breast Cancer Management: A Brief Review

Contact Info

Product

Resources

About